Table 2 Analysis of survival time of Smad4-positive and Smad4-negative patients stratified with regard to tumor stage, ER-status, TβRI-status, and TβRII-status. 5-year survival rates were computed by the Kaplan-Meier estimator. Survival curves were compared by log-rank test (n = 197).
From: Smad4-expression is decreased in breast cancer tissues: a retrospective study
| Â | 5 year survival | Total number | Log rank test | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Number censored | p | |
| Â | Smad4 negative | Smad4 positive | Smad4 negative | Smad4 positive | Smad4 negative | Smad4 positive | Â |
Unstratified | 92.4 | 74.5 | 44 | 153 | 35 | 111 | 0.187 |
WHO I | 100.0* | 86.7 | 11 | 24 | 11 | 19 | 0.135 |
WHO II | 94.4 | 81.3 | 19 | 89 | 15 | 71 | 0.821 |
WHO III | 92.3 | 54.7 | 13 | 34 | 9 | 19 | 0.137 |
WHO IV | 0 | 20.8 | 1 | 6 | 0 | 2 | 0.661 |
WHO I/II | 96.2 | 82.5 | 30 | 113 | 26 | 90 | 0.32 |
WHO III/IV | 84.4 | 50.2 | 14 | 40 | 9 | 21 | 0.121 |
T1 | 100.0 | 83.7 | 15 | 37 | 14 | 29 | 0.209 |
T2 | 93.3 | 71.2 | 15 | 84 | 11 | 57 | 0.448 |
T3 | 87.5 | 63.5 | 8 | 12 | 5 | 8 | 0.899 |
T4 | 50.0 | 45.5 | 6 | 20 | 2 | 9 | 0.588 |
N0 | 94.1 | 88.1 | 18 | 64 | 16 | 52 | 0.425 |
N1 | 91.1 | 59.0 | 23 | 77 | 15 | 45 | 0.167 |
N2 | 50.0 | 52.5 | 2 | 8 | 1 | 4 | 0.666 |
N3 | 0 | 50.0 | 1 | 4 | 0 | 2 | 0.948 |
N1–3 | 84.3 | 57.9 | 26 | 89 | 16 | 51 | 0.227 |
ER negative | 93.8 | 66.5 | 16 | 59 | 13 | 41 | 0.278 |
ER positive | 91.7 | 78.9 | 28 | 94 | 22 | 70 | 0.474 |
TβRI negative | 94.1 | 76.5 | 17 | 24 | 16 | 19 | 0.245 |
TβRI positive | 92.3 | 74.1 | 27 | 129 | 19 | 92 | 0.523 |
TβRII negative | 100.0 | 80 | 19 | 39 | 17 | 30 | 0.133 |
TβRII positive | 85.9 | 72.8 | 25 | 114 | 18 | 81 | 0.806 |